No abstract available
Keywords:
ACE2; SARS-CoV-2; coronavirus; diminazene; lung injury; pharmacology.
MeSH terms
-
Adaptive Immunity / drug effects
-
Angiotensin-Converting Enzyme 2
-
Antiviral Agents / pharmacology*
-
Betacoronavirus* / drug effects
-
Betacoronavirus* / physiology
-
COVID-19
-
Coronavirus Infections* / drug therapy
-
Coronavirus Infections* / immunology
-
Coronavirus Infections* / virology
-
Drug Discovery
-
Humans
-
Lung / metabolism
-
Pandemics*
-
Peptidyl-Dipeptidase A / metabolism*
-
Pneumonia, Viral* / drug therapy
-
Pneumonia, Viral* / immunology
-
Pneumonia, Viral* / virology
-
Receptors, Virus / metabolism
-
SARS-CoV-2
-
Spike Glycoprotein, Coronavirus / metabolism*
-
Treatment Outcome
-
Virus Internalization / drug effects
Substances
-
Antiviral Agents
-
Receptors, Virus
-
Spike Glycoprotein, Coronavirus
-
spike protein, SARS-CoV-2
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2
Grants and funding
The authors gratefully acknowledge the financial support from CNPq (Brazil) and Research Foundation for the State of Piauí—FAPEPI.